Twist Bioscience and Cancer Research Horizons announce new collaboration
The Library of Libraries is an ‘expansive’ collection of synthesized antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years.
Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.
Emily Leproust, CEO and co-founder of Twist Bioscience, said: “Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients.”
“Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our ‘Library of Libraries.’ With two mission-driven organizations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.”
Hamish Ryder, CEO of therapeutic innovation at Cancer Research Horizons, added: “We’re delighted to partner with Twist Bioscience, an exciting technology platform company who will enhance our antibody discovery capabilities with their highly diverse phage display libraries.”
“We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners.”
According to Twist Bioscience, its Library of Libraries gives its partners an ‘integral’ and ‘unbiased’ resource for antibody therapeutic discovery and optimization.
The company said its 'precise and rational’ approach to library fabrication, combined with bioinformatics and software expertise, expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
